PPARγ agonists may potentiate the cytotoxic effect of valproic acid in MM cells [72], and early in vitro studies suggested that all-trans retinoic acid can potentiate the anti-MM cell effect of rosiglitazone [73]. The gene discussed is PPARG; the disease is Miyoshi myopathy.